Lead Sponsor

University of Chicago

Age

1 - No limit years

Sex

ALL

Healthy Volunteers

No

•Patients will be eligible for this study if they have any one of the diseases that are known to be cured after allogeneic stem cell transplantation.
•1. Relapsed or refractory acute leukemia (myeloid or lymphoid)
•2. Acute leukemia in first remission at high-risk for recurrence
•3. Chronic myelogenous leukemia in accelerated phase or blast-crisis
•4. Chronic myelogenous leukemia in chronic phase
•5. Recurrent or refractory malignant lymphoma or Hodgkin lymphoma
•6. Chronic lymphocytic leukemia, relapsed or with poor prognostic features
•7. Multiple myeloma
•8. Myelodysplastic syndrome
•9. Chronic myeloproliferative disease
•10. Hemoglobinopathies
•11. Aplastic anemia

•1. Zubrod performance status \> 2
•2. Life expectancy is severely limited by concomitant illness
•3. Patients with severely decreased LVEF or impaired pulmonary function tests(PFT's)
•4. Estimated Creatinine Clearance \<50 ml/min
•5. Serum bilirubin\> 2.0 mg/dl or SGPT \>3 x upper limit of normal
•6. Evidence of chronic active hepatitis or cirrhosis
•7. HIV-positive
•8. Patient is pregnant
•9. Patient or guardian not able to sign informed consent

Related studies

NCT06735690 · Acute Lymphoblastic Leukemia

NCT06303193 · Myelodysplastic Syndromes

NCT07249528 · Non-hodgkin Lymphoma, Multiple Myeloma

NCT00131014 · Non-Hodgkin's Lymphoma, Hodgkin's Disease, and more

NCT05564390 · Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, and more

Combined Haploidentical-Cord Blood Transplantation for Adults and Children